#83 Muscarinic receptors subtypes M2 and M3 in human urinary bladder disorders and their clinical correlations

#84 Quality of Life Following Treatment With Transdermal Oxybutynin: The Effects of Prior Therapy

#85 Seasonal differences in patterns of improvement in urinary symptoms for Japanese OAB patients treated by the oxbutynin

#86 Patient-reported reasons for discontinuing overactive bladder (OAB) medications

#87 DIFFERENTIAL EFFECTS OF THE ANTIMUSCARINIC AGENTS TOLTERODINE TARTRATE ER AND OXYBUTYNIN CHLORIDE ER ON RECENT MEMORY IN OLDER SUBJECTS

#88 EFFICACY OF TOLTERODINE VARIES IN RELATION TO DIFFERENT URODYNAMIC FINDINGS OF DETRUSOR OVERACTIVITY

#89 Comparison of solifenacin 5 mg and tolterodine ER 4 mg in the STAR OAB study

#90 Antidiuresis in the treatment of overactive bladder syndrome

#91 A Pilot Study to Assess the Effect of Treatment with an NK-1 Receptor Antagonist on Urge Urinary Incontinence Symptoms

#92 Nicorandil, a KATP channel opener and nitric oxide donor, was effective in the treatment of urinary frequency – a randomized clinical trial

#93 A Randomised Double-Blind Placebo Controlled Study to evaluate the Efficacy of Tamsulosin OCAS in the Management of Women with Overactive Bladder.

#94 Randomised Controlled Trial of Cannabis Based Medicine (CBM, Sativex®) to treat Detrusor Overactivity in Multiple Sclerosisdetect a difference